A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To determine objective response rate (ORR).
Secondary Objectives:
To assess duration of response (DR), progression free survival (PFS) and overall survival
(OS).
To evaluate global safety profile. To determine pharmacokinetic profile. To assess clinical
utility of fluorescence in situ hybridization (FISH) assay in selection of patients with
mesenchymal-epithelial hybridization (MET) gene amplification.
To assess lung cancer symptoms, health-related quality of life and treatment satisfaction.